COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Clinicians who participate in a clinical trial for a drug or biological product to treat a patient with novel coronavirus may now earn credit in the Merit-based Incentive Payment System, the Centers for Medicare & Medicaid Services announced.
The Food and Drug Administration authorized the first diagnostic test with a home collection option for COVID-19.
The Food and Drug Administration said that it will temporarily forgo action against 503A compounding pharmacies that provide to hospitals certain compounded drugs without patient-specific prescriptions.
The Centers for Medicare & Medicaid Services April 21 and April 23 will host calls for hospitals, health systems and providers on COVID-19.
The Centers for Medicare & Medicaid Services issued updated guidance on providing essential non-COVID-19 care to patients without symptoms of COVID-19 in regions with low and stable incidence of the virus.
The Centers for Medicare & Medicaid Services (CMS) last night issued updated guidance on providing essential non-COVID-19 care to patients without symptoms of COVID-19 in regions with low and stable incidence of the virus. This is part of Phase 1 in the Administration’s Guidelines for Opening…
Statement on CMS guidance on elective procedures from AHA President and CEO Rick Pollack.
The Food and Drug Administration encouraged those who have recovered from COVID-19 to donate plasma for the creation of convalescent plasma, an antibody-rich investigational therapy that may help others fight the disease.
The Food and Drug Administration issued guidance expanding the use of telethermographic systems for triage use during the public health crisis.
The Centers for Disease Control and Prevention has collated in one location training materials for health care professionals during the COVID-19 emergency, including webinars, videos and online courses.